OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

OptimizeRx reported third-quarter 2026 revenue of $21.6 million, down 17% from $26.1 million a year earlier, and GAAP net income of $1.2 million, or $0.06 per share. The company lowered its fiscal 2026 revenue guidance to $87 million–$93 million while maintaining adjusted EBITDA guidance of $21 million–$25 million. Since June 30, 2026, it has repaid $9.3 million of debt principal, reducing outstanding principal to $10.4 million. Management cited lower in-year contracted revenue as the reason for the revised outlook and pointed to expected growth in 2027 contracted revenue and the upcoming RFP season.